Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Delhi based Fortis Hospital receives Aethlon Medical’s Hemopurifier shipments

Aethlon Medical : 05 September, 2007  (New Product)
Aethlon Medical has shipped Hemopurifier treatment cartridges to support a clinical study to be conducted at the Fortis Hospital in Delhi, India.
The study, which will evaluate the safety of the Hemopurifier in ten patients, is expected to commence in the coming month.

The Fortis study reinforces Aethlon's strategy to pursue early treatment and commercialisation opportunities in India.

Aethlon will focus on viral conditions of greatest concern to Indian citizens, and opportunities that offer treatment access to the Hemopurifier within India's growing medical tourism industry.

Targeted conditions may include Dengue Haemorrhagic Fever (DHF), HIV/AIDS, and Hepatitis-C (HCV). Pending the accumulation of further data, Aethlon may also pursue opportunities to implement the Hemopurifier as an adjunct therapy for cancer in the region.

Commercialisation of the Hemopurifier into the Indian marketplace will be based on obtaining sufficient clinical data to drive practitioner acceptance in the marketplace.

Dr Vijay Kher, director of Nephrology at Fortis Hospital, has been named the principal investigator of the study. Previously, Dr Kher acted as principal investigator of a Hemopurifier study conducted at the Apollo Hospital in Delhi.

The Apollo study documented initial safety of the Hemopurifier, and provided early efficacy observations during 24-treatments administered to health compromised dialysis patients co-infected with HCV.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo